CN102274396A - 治疗糖尿病肾病的中药及其制备方法 - Google Patents
治疗糖尿病肾病的中药及其制备方法 Download PDFInfo
- Publication number
- CN102274396A CN102274396A CN201110208661XA CN201110208661A CN102274396A CN 102274396 A CN102274396 A CN 102274396A CN 201110208661X A CN201110208661X A CN 201110208661XA CN 201110208661 A CN201110208661 A CN 201110208661A CN 102274396 A CN102274396 A CN 102274396A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- treatment
- chinese medicine
- diabetic nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 53
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 36
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 claims abstract description 36
- 239000009636 Huang Qi Substances 0.000 claims abstract description 20
- 241001522129 Pinellia Species 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 104
- 241000208340 Araliaceae Species 0.000 claims description 35
- 241000237636 Pheretima Species 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 9
- 241000545442 Radix Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 48
- 210000004369 blood Anatomy 0.000 abstract description 45
- 210000003734 kidney Anatomy 0.000 abstract description 39
- 229940079593 drug Drugs 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 22
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 230000007812 deficiency Effects 0.000 abstract description 11
- 230000027939 micturition Effects 0.000 abstract description 6
- 206010013954 Dysphoria Diseases 0.000 abstract description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 206010037660 Pyrexia Diseases 0.000 abstract description 5
- 210000003127 knee Anatomy 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 231100000614 poison Toxicity 0.000 abstract description 5
- 230000035807 sensation Effects 0.000 abstract description 5
- 235000019615 sensations Nutrition 0.000 abstract description 5
- 230000002269 spontaneous effect Effects 0.000 abstract description 5
- 239000002574 poison Substances 0.000 abstract description 4
- 208000009205 Tinnitus Diseases 0.000 abstract description 3
- 231100000886 tinnitus Toxicity 0.000 abstract description 3
- 230000036565 night sweats Effects 0.000 abstract description 2
- 206010029410 night sweats Diseases 0.000 abstract description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 235000019605 sweet taste sensations Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 210000002700 urine Anatomy 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 16
- 238000002562 urinalysis Methods 0.000 description 15
- 238000011002 quantification Methods 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 230000010354 integration Effects 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 230000035922 thirst Effects 0.000 description 10
- 229940126678 chinese medicines Drugs 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 9
- 230000003908 liver function Effects 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010001580 Albuminuria Diseases 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010057186 Insulin Glargine Proteins 0.000 description 5
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- 229940060975 lantus Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000002555 auscultation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960002869 insulin glargine Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102100022361 CAAX prenyl protease 1 homolog Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000824531 Homo sapiens CAAX prenyl protease 1 homolog Proteins 0.000 description 1
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000034777 Vitreous degeneration Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940006384 glipizide 2.5 mg Drugs 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008720 membrane thickening Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 201000011288 vitreous syneresis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
项目 | 治疗组(n=30) | 对照组(n=30) |
尿蛋白(mg/24h) | 132.6士79.39 | 130.2士76.83 |
NF-κB(mg/L) | 0.76士0.13 | 0.81±0.19 |
项目 | 治疗组(n=30) | 对照组(n=30) |
TC(mmol/L) | 5.25士1.54 | 5.38士1.36 |
TG(mmol/L) | 3.76士1.79 | 3.79士1.64 |
HDL-C(mg/dl) | 0.77士0.15 | 0.76士0.21 |
LDL-C(mg/dl | 3.96士0.97 | 3.75士1.03 |
项目 | 治疗组(n=30) | 对照组(n=30) |
FPG(mmol/L) | 7.47士1.39 | 7.65士1.16 |
2hPG(mmol/L) | 8.94士1.51 | 9.24士1.53 |
HbAlc(%) | 7.12士1.04 | 7.11士1.23 |
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率 |
治疗组 | 30 | 16(53.33) | 12(40.00) | 2(6.67) | 93.33 |
对照组 | 30 | 10(33.33) | 16(53.33) | 4(13.33) | 89.99 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110208661A CN102274396B (zh) | 2011-07-25 | 2011-07-25 | 治疗糖尿病肾病的中药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110208661A CN102274396B (zh) | 2011-07-25 | 2011-07-25 | 治疗糖尿病肾病的中药及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102274396A true CN102274396A (zh) | 2011-12-14 |
CN102274396B CN102274396B (zh) | 2012-09-26 |
Family
ID=45100340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110208661A Expired - Fee Related CN102274396B (zh) | 2011-07-25 | 2011-07-25 | 治疗糖尿病肾病的中药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102274396B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690784A (zh) * | 2013-12-31 | 2014-04-02 | 王雪雁 | 治疗糖尿病肾病合并高血压肾病的中药组合物及制备方法 |
CN104547614A (zh) * | 2014-12-31 | 2015-04-29 | 曾子维 | 一种药物组合物在制备治疗糖尿病肾病药物中的用途 |
CN106038926A (zh) * | 2016-08-16 | 2016-10-26 | 汪培杰 | 一种治疗糖尿病的中药及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449777A (zh) * | 2002-04-09 | 2003-10-22 | 韩玉昆 | 一种治疗肾脏疾病的药物 |
-
2011
- 2011-07-25 CN CN201110208661A patent/CN102274396B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449777A (zh) * | 2002-04-09 | 2003-10-22 | 韩玉昆 | 一种治疗肾脏疾病的药物 |
Non-Patent Citations (1)
Title |
---|
《北京中医》 20020625 洪昱钤 糖尿病肾病的中医药研究进展 187-189 1-5 第21卷, 第03期 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690784A (zh) * | 2013-12-31 | 2014-04-02 | 王雪雁 | 治疗糖尿病肾病合并高血压肾病的中药组合物及制备方法 |
CN104547614A (zh) * | 2014-12-31 | 2015-04-29 | 曾子维 | 一种药物组合物在制备治疗糖尿病肾病药物中的用途 |
CN106038926A (zh) * | 2016-08-16 | 2016-10-26 | 汪培杰 | 一种治疗糖尿病的中药及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102274396B (zh) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988750B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN101134083A (zh) | 用于治疗糖尿病及其并发症的中草药胶囊及其制备方法 | |
CN104645132B (zh) | 一种治疗糖尿病肾病的中药组合物、制备方法、中药制剂及应用 | |
CN111658701A (zh) | 一种健脾中药组合物及其应用 | |
CN104288412B (zh) | 一种治疗代谢综合征的中药组合物 | |
CN101428113A (zh) | 一种治疗2型糖尿病的中药制剂及其制备方法 | |
CN102813870B (zh) | 一种治疗酒精中毒痛风的中药复方制剂及制备方法与应用 | |
CN102302740B (zh) | 一种治疗心肾阴虚型胸痹的中药制备方法 | |
CN102274396B (zh) | 治疗糖尿病肾病的中药及其制备方法 | |
CN102872423B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
CN109498731A (zh) | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 | |
CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN113521134B (zh) | 一种用于治疗ii型糖尿病的中药组合物与应用 | |
CN102526631B (zh) | 治疗扩张型心肌病的中药制剂、片剂、胶囊剂及制备方法 | |
CN101843843A (zh) | 一种治疗糖尿病的中药 | |
CN104324261A (zh) | 治疗高血糖的药物组合物及其制备方法 | |
CN104367753B (zh) | 一种治疗2型糖尿病的中药组合物 | |
CN103751558B (zh) | 一种复方降糖丸剂及其制备方法 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102935214B (zh) | 一种治疗尿毒症的中药组合物 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN104107227B (zh) | 治疗糖尿病肾病的中药直肠滴剂及其制备方法 | |
CN102366480A (zh) | 一种治疗糖尿病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE Free format text: FORMER OWNER: SUN XINYU Effective date: 20150401 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 450002 ZHENGZHOU, HENAN PROVINCE TO: 450008 ZHENGZHOU, HENAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150401 Address after: 450008 Jinshui Road, Zhengzhou, Henan, No. 1 Patentee after: Henan University of Traditional Chinese Medicine Address before: 6 Department of Endocrinology, Henan Traditional Chinese Medicine Hospital, Dongfeng Road, Jinshui District, Henan, Zhengzhou 450002, China Patentee before: Sun Xinyu |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120926 Termination date: 20150725 |
|
EXPY | Termination of patent right or utility model |